Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KINDRED BIOSCIENCES, INC.

(KIN)
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Kindred Biosciences, Inc. Announces Board Changes

08/30/2021 | 09:06am EST

On August 27, 2021, Kindred Biosciences, Inc., (KindredBio), was acquired by Elanco Animal Health Incorporated, (Elanco), pursuant to the merger of Knight Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Elanco (Merger Sub), with and into KindredBio, with KindredBio surviving the merger as a wholly owned subsidiary of Elanco (Merger). The Merger was effected pursuant to the previously announced Agreement and Plan of Merger, dated as of June 15, 2021 (as amended by the First Amendment, dated June 30, 2021 (the First Amendment), the Merger Agreement), by and among KindredBio, Elanco and Merger Sub. In connection with the consummation of the Merger, all of the members of KindredBio's board of directors resigned from the Board and from all committees of the Board on which such directors served, effective as of the Effective Time. These resignations were not a result of any disagreements between KindredBio and the former directors on any matter relating to KindredBio's operations, policies or practices. Upon consummation of the Merger on August 27, 2021, pursuant to the Merger Agreement, the directors of Merger Sub immediately prior to the Effective Time, consisting of David Pugh, Kathleen St. Louis and Jinee Majors, became the directors of KindredBio. Also in accordance with the terms of the Merger Agreement, at the Effective Time, the officers of KindredBio were effectively removed and replaced by the officers of Merger Sub, effective at the Effective Time.


ę S&P Capital IQ 2021
All news about KINDRED BIOSCIENCES, INC.
2021Vaxart, Inc. acquired KindredBio's manufacturing equipment and GMP manufacturing facili..
CI
2021KINDRED BIOSCIENCES : Market Offering Agreement (Form 8-K)
PU
2021KINDRED BIOSCIENCES, INC. : Termination of a Material Definitive Agreement, Completion of ..
AQ
2021Kindred Biosciences, Inc. Announces Board Changes
CI
2021ELANCO ANIMAL HEALTH INCORPORATED : Closes Purchase of Kindred Biosciences for About $444 ..
MT
2021KINDRED BIOSCIENCES, INC.(NASDAQCM : KIN) dropped from S&P Global BMI Index
CI
2021KINDRED BIOSCIENCES, INC.(NASDAQCM : KIN) dropped from S&P TMI Index
CI
2021KINDRED BIOSCIENCES, INC.(NASDAQGM : KIN) dropped from NASDAQ Composite Index
CI
2021Elanco Animal Health Incorporated completed the acquisition of Kindred Biosciences, Inc..
CI
2021KINDRED BIOSCIENCES, INC. : Submission of Matters to a Vote of Security Holders, Financial..
AQ
More news
Analyst Recommendations on KINDRED BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2020 3,46 M - -
Net income 2020 -21,8 M - -
Net cash 2020 35,0 M - -
P/E ratio 2020 -7,77x
Yield 2020 -
Capitalization 421 M 421 M -
EV / Sales 2019 66,3x
EV / Sales 2020 39,0x
Nbr of Employees 63
Free-Float 81,0%
Chart KINDRED BIOSCIENCES, INC.
Duration : Period :
Kindred Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Hangjun Zhan Chief Scientific Officer
Katja Buhrer COO & VP-Corporate Development & Investor Relation
David Pugh Director
Kathleen St. Louis Director
Jinee Majors Director
Sector and Competitors
1st jan.Capi. (M$)
KINDRED BIOSCIENCES, INC.114.62%421
GILEAD SCIENCES, INC.-5.65%85 938
REGENERON PHARMACEUTICALS-1.60%64 971
VERTEX PHARMACEUTICALS3.86%57 990
WUXI APPTEC CO., LTD.-5.63%49 645
BIONTECH SE-42.79%35 624